Glucagon-like peptide-1 (GLP-1) and its analogs are widely used for diabetes treatment. The
paraventricular nucleus (PVN) is crucial for regulating cardiovascular activity. This study …

The central administration of glucagon-like peptide-2 (GLP-2) decreases blood pressure in
rats. In the present study, we investigated the hypotensive effects of GLP-2 using …

Glucagon-like peptide-1 (GLP-1), an incretin, which is used to treat diabetes mellitus in
humans, inhibited vagal activity and activated nitrergic pathways. In rats, GLP-1 also …

Within the brain, glucagon-like peptide-1 (GLP-1) affects central autonomic neurons,
including those controlling the cardiovascular system, thermogenesis, and energy balance …

OBJECTIVE—To ascertain the importance and mechanisms underlying the role of brain
glucagon-like peptide (GLP)-1 in the control of metabolic and cardiovascular function. GLP-1 …

Abstract Glucagon-like peptide-1 receptor (GLP-1R) agonists, widely used to treat type 2
diabetes, reduce blood pressure (BP) in hypertensive patients. Whether this action involves …

Abstract Background Glucagon-like peptide-1 (GLP-1) induces diuresis and natriuresis.
Previously we have shown that GLP-1 activates afferent renal nerve to increase efferent …

Glucagon-like peptide-1 (GLP-1) released from the gut functions as an incretin that
stimulates insulin secretion. GLP-1 is also a brain neuropeptide that controls feeding and …

Background: Idiopathic intracranial hypertension (IIH) predominantly affects obese women
of childbearing age. IIH is characterised by increased intracranial pressure (ICP) which …

Abstract Objectives Glucagon-like peptide-1 (GLP-1) is secreted from enteroendocrine cells
and exerts a broad number of metabolic actions through activation of a single GLP-1 …